Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.70 is 61% above its 5-year average of -1.81, near the high end of its 5-year range (-2.49–-0.70).
40.93% above its 12-month average of -1.19.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.11.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.70
EARNINGS PER SHARE (EPS) AVG TTM
-1.19
EARNINGS PER SHARE (EPS) AVG 3Y
-1.69
EARNINGS PER SHARE (EPS) AVG 5Y
-1.81
EARNINGS PER SHARE (EPS) AVG 10Y
-1.51
EARNINGS PER SHARE (EPS) AVG 15Y
-1.75
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+40.93%
CURRENT VS 3Y AVG
+58.52%
CURRENT VS 5Y AVG
+61.33%
CURRENT VS 10Y AVG
+53.67%
CURRENT VS 15Y AVG
+60.08%
CURRENT VS 20Y AVG
N/A
Iovance Biotherapeutics, Inc.
Market Cap
$5.90B
Earnings Per Share (EPS)
-0.70
TTM Avg
-1.19
3Y Avg
-1.69
5Y Avg
-1.81
Market Cap
$5.92B
Earnings Per Share (EPS)
9.35
TTM Avg
3.11
3Y Avg
1.82
5Y Avg
1.76
Market Cap
$6.02B
Earnings Per Share (EPS)
-9.75
TTM Avg
-37.33
3Y Avg
-73.93
5Y Avg
-56.40
Market Cap
$5.74B
Earnings Per Share (EPS)
0.98
TTM Avg
0.10
3Y Avg
0.76
5Y Avg
-0.31
Market Cap
$5.67B
Earnings Per Share (EPS)
-2.70
TTM Avg
-1.75
3Y Avg
-1.29
5Y Avg
-1.09
Market Cap
$5.54B
Earnings Per Share (EPS)
-0.27
TTM Avg
-0.11
3Y Avg
0.01
5Y Avg
0.03
Market Cap
$6.25B
Earnings Per Share (EPS)
-3.11
TTM Avg
-3.72
3Y Avg
-3.54
5Y Avg
-3.08
Market Cap
$5.53B
Earnings Per Share (EPS)
-1.10
TTM Avg
-1.09
3Y Avg
-0.73
5Y Avg
-0.73
Market Cap
$5.32B
Earnings Per Share (EPS)
0.85
TTM Avg
1.12
3Y Avg
0.90
5Y Avg
0.76
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Iovance Biotherapeutics, Inc. (IOVA) | $5.90B | -0.70 | -1.19 | -1.69 | -1.81 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.92B | 9.35 | 3.11 | 1.82 | 1.76 |
| GRAIL Inc. (GRAL)vs › | $6.02B | -9.75 | -37.33 | -73.93 | -56.40 |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 0.98 | 0.10 | 0.76 | -0.31 |
| CG Oncology Inc. (CGON)vs › | $5.67B | -2.70 | -1.75 | -1.29 | -1.09 |
| RadNet, Inc. (RDNT)vs › | $5.54B | -0.27 | -0.11 | 0.01 | 0.03 |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.25B | -3.11 | -3.72 | -3.54 | -3.08 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.53B | -1.10 | -1.09 | -0.73 | -0.73 |
| Doximity, Inc. (DOCS)vs › | $5.32B | 0.85 | 1.12 | 0.90 | 0.76 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | -0.58 | 1.92 | -3.08 | -4.40 |
Trailing EPS (TTM)
$-0.70
Forward EPS (Est.)
$-0.45
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.09 |
| 2024-12-31 | -1.28 |
| 2023-12-31 | -1.89 |
| 2022-12-31 | -2.49 |
| 2021-12-31 | -2.23 |
| 2020-12-31 | -1.88 |
| 2019-12-31 | -1.50 |
| 2018-12-31 | -1.27 |
| 2017-12-31 | -1.41 |
| 2016-12-31 | -0.96 |
| 2015-12-31 | -0.62 |
| 2014-12-31 | -0.48 |
| 2013-12-31 | -2.60 |
| 2012-12-31 | -4.14 |
| 2011-12-31 | -33.84 |
| 2010-12-31 | -2.46 |
| 2009-12-31 | -0.02 |
| 2008-12-31 | -0.05 |
